International Markets Presentation
Released
Released
Announcement PDF
FY26 INVESTOR UPDATE
International
Markets
FY26 review and FY27 priorities
Prepared by Biome Australia Limited · July 2026
ASX: BIO
IMPORTANT NOTICE
Disclaimer and forward-looking statements
This presentation is provided for information purposes only and should be read together with Biome Australia Limited’s ASX
announcements and financial reports.
Not financial advice
This presentation is not a prospectus, product disclosure
statement or other offering document, and does not
constitute an offer, invitation or recommendation to
subscribe for or purchase any securities.
It does not take into account the investment objectives,
financial situation or particular needs of any individual.
Investors should seek independent professional advice.
Forward-looking statements
Statements about future events, plans, priorities, market
expansion, margin and manufacturing outcomes are
forward-looking and involve known and unknown risks and
assumptions.
Actual results may differ materially. Biome undertakes no
obligation to update forward-looking statements except as
required by law.
Data and estimates
Financial information is unaudited unless stated. Domestic
and international splits are estimates. Market size, category
growth and pharmacy figures are drawn from third-party
sources cited on the relevant slide.
Illustrative material is provided to explain the operating
model and is not a forecast.
BIOME AUSTRALIA LIMITED ACN 626 435 500 · ASX: BIO · All figures in Australian dollars unless otherwise stated.
BIOME AUSTRALIA · ASX: BIO 2
OUR MISSION
To prevent disease, improve health outcomes and
quality of life, and make our products accessible to
all.
Biome Australia Limited · ASX: BIO
CERTIFIED B CORPORATION
Proud to be B Corp certified
Certified B Corporations are leaders in the global movement for an
inclusive, equitable and regenerative economy by committing and
demonstrating:
● Responsible social and environmental practices that benefit employees and the
wider community
● A corporate governance structure that emphasises accountability
● Transparency by allowing information about performance to be publicly available on
B Lab
Biome Australia Limited · ASX: BIO
COMPANY OVERVIEW
About Biome Australia
Clinically-proven, condition-specific probiotics, developed with
world-leading microbiome research partners.
Biome Australia (ASX: BIO) is focused on becoming a global leader
in the complementary medicine industry, offering clinically-proven,
condition-specific probiotic products fuelled by novel clinical
research programs to cement and extend the evidence base of its
probiotic products.
Activated Probiotics, Biome’s flagship range of novel
live-biotherapeutics (probiotics), was created in partnership with
world leading organisations in microbiome research and utilises
innovative delivery technologies that improve their stability and
efficacy.
BIOME AUSTRALIA · ASX: BIO 5
FY26 IN NUMBERS
FY26 international performance
Four markets contributing, with operating leverage beginning to show
FY26 INT'L REVENUE
$1.8m
+26% on FY25
INT'L GROSS MARGIN
~68%
7pp above domestic
INT'L DISTRIBUTION
POINTS
~2,000
and growing rapidly
INTERNATIONAL FTE
12
Across four markets
APPROACHING
BREAKEVEN
approaching
breakeven
$1.8m revenue vs $1.82m
opex
Practitioner-only and clinically backed in every market. First mover in a category where every other brand sells online
and through discounters.
BIOME AUSTRALIA · ASX: BIO 6
THE AUSTRALIAN MARKET
The Australian model
Australia scaled from 100 to 7,500 points of sale in six years to become the #1 probiotic product in Australian pharmacy₁
(Biome Daily),
on a practitioner-led, non-discounted model. The same model is now running across four international markets.
AUSTRALIA / POINTS OF SALE
~106%
6-year CAGR in AU points of sale (FY20–FY26)
● Same-store sales grew +38.6% in comparable accounts in FY26, with
~1,600 new AU accounts added in FY26
● International markets are at the early, steep part of the same curve
● If replicated, each market compounds distribution the way AU did
from a standing start
Australian points of sale are actuals. International replication is illustrative of the model, not a forecast.
BIOME AUSTRALIA · ASX: BIO 7
1. IQVIATM
Out Service, VITAMINS MINERALS AND SUPPLEMENTS category, CHC3=PROBIOTICS, Australia Pharmacy, Total Value and Unit, 52 Weeks W/E 2026-06-27. (IQVIA Australian Company Number 000 967 859 Copyright © 2026 IQVIA. All rights reserved)
#1 IN AUSTRALIA / SCALING TO THE WORLD
Category position in Australia
Two #1 products in Australian pharmacy scan sales (FY26), on the platform to scale internationally in FY27.
#1
Biome Daily Probiotic
The number one probiotic product in Australian pharmacy1
Flagship daily probiotic
#1
Biome Daily Kids Probiotic
The number one Kids probiotic and immune health probiotic
in Australian pharmacy1
Children's immune health
Premium Practitioner-only Clinically backed Non discounted
1. IQVIATM
Out Service, VITAMINS MINERALS AND SUPPLEMENTS category, CHC3=PROBIOTICS, Australia Pharmacy, Total Value and Unit, 52 Weeks W/E 2026-06-27. (IQVIA Australian Company Number 000 967 859
Copyright © 2026 IQVIA. All rights reserved)
BIOME AUSTRALIA · ASX: BIO 8
OPERATING LEVERAGE
Operating leverage emerging
Revenue growth outpaced cost growth in FY26. Group gross profit of $1.21m at 68%, with net loss narrowing to $649k.
The build phase is behind us
Group gross profit $1,214k at a blended 68% margin; net loss
narrowed to $649k. Approaching breakeven.
FY27
Priorities locked across all four markets, on infrastructure already
built.
Beyond
Contribution flip implied as revenue scales on stable headcount.
BIOME AUSTRALIA · ASX: BIO 9
$1.80m
$1.21m
$1.82m
FY26
Revenue Gross profit Operating expenses
FY26 GROUP PERFORMANCE · A$M
GLOBAL FOOTPRINT
Four active markets
Independent demand across each market, with an optimised channel mix per jurisdiction.
GROWING
Canada
Fullscript & Ecotrend
NH HUB
United Kingdom
NH sales, marketing &
distribution
SCALING
Ireland
Uniphar 18 → 40 stores
LAUNCHING
New Zealand
ProPharma & Practitioner
BIOME AUSTRALIA · ASX: BIO 10
MARKET DEEP DIVE · CANADA / OPPORTUNITY
Canada
The largest international contributor, now deepening: five distribution partners across practitioner, pharmacy and health-food
channels.
GROWING PROBIOTICS MARKET
US$2.5bn
2023, Grand View Research
CATEGORY GROWTH
~13% p.a.
CAGR to 2030
THE MOAT Practitioner-only • Clinically backed • Non discounted • Unlike any brand in any market
11
CHANNELS
Practitioner Pharmacy retail Health-food retail
BIOME AUSTRALIA · ASX: BIO
MARKET DEEP DIVE · CANADA / EXECUTION
Canada — execution
Deepening across channels: the practitioner platform anchored by Fullscript and Ecotrend, with pharmacy and health-food retail
secured in FY26.
PARTNERS & DISTRIBUTORS
Pure Pharmacy
Integrative pharmacy retail — secured FY26
Health Food Network
Health-food retail — secured FY26
Practitioner Direct
Direct clinic supply
Fullscript
125k+ NH practitioners on platform
Ecotrend Ecologics
National wholesale distribution
COMPETITORS — WHAT WE DO BETTER
Genestra
Them: Broad practitioner range, legacy brand
Us: Proprietary clinically-trialled strains, tighter focus
Metagenics
Them: Scale, but discounts into retail
Us: Never discounted; channel integrity protected
NFH
Them: Practitioner-only, research-led
Us: Owned IP (BMB18) plus onshore AU manufacturing
HOW WE SCALE
● Unlock Quebec market
● Bring FY26 retail banner wins online
● Expand Health Canada approvals (12 → 24
SKUs)
● Deepen practitioner education footprint
12
BIOME AUSTRALIA · ASX: BIO
MARKET DEEP DIVE · UNITED KINGDOM / OPPORTUNITY
United Kingdom
Our Northern Hemisphere hub: distribution, sales and marketing for the EU and Canada run from the UK, alongside a measured
practitioner-in-clinic market.
NH HUB
NORTHERN HEMISPHERE HUB
A long-term margin play: manufacturing
optimisation plus higher UK/EU RRPs.
HUB ROLE
Sales · Marketing · Distribution
run from the UK
THE MOAT Practitioner-only • Clinically backed • Non discounted • Unlike any brand in any market
13
CHANNELS
In-clinic practitioners Doctors Nutritional therapists
BIOME AUSTRALIA · ASX: BIO
MARKET DEEP DIVE · UNITED KINGDOM / EXECUTION
United Kingdom — execution
A hub-first model: the UK team runs Northern Hemisphere operations, with the practitioner market served through specialist
distributors.
PARTNERS & DISTRIBUTORS
The Natural Dispensary
Primary practitioner distribution partner
Amrita UK
practitioner distributor
TDS (Northern Ireland)
3PL — direct UK + EU supply
COMPETITORS — WHAT WE DO BETTER
Symprove
Them: Strong DTC brand, liquid format
Us: Practitioner-endorsed, clinically-trialled strains
OptiBac
Them: Retail-heavy, promotional pricing
Us: Never discounted; practitioner-in-clinic positioning
Bio-Kult
Them: Mass pharmacy presence
Us: Owned IP and recommendation-driven demand
HOW WE SCALE
● Run EU + Canada sales and marketing
from the UK
● Deepen clinic and NT practitioner base
● Test Biome B2B2C + eScript portal (H1
FY27)
● Leverage TDS hub for EU supply
14
BIOME AUSTRALIA · ASX: BIO
MARKET DEEP DIVE · IRELAND / OPPORTUNITY
Ireland
A strong long-term pharmacy market: 50% of Irish supplement sales still go through pharmacy. Five banner groups secured in FY26,
more onboarding in FY27.
SCALING REGISTERED PHARMACIES
1,989
end-2024, PSI register
SUPPLEMENTS GROWTH
~8% p.a.
Category trend
PHARMACY BANNERS LAUNCHED FY26
McCauleys Hickeys Allcare
Further banners onboarding in FY27.
THE MOAT Practitioner-only • Clinically backed • Non discounted • Unlike any brand in any market
15
BIOME AUSTRALIA · ASX: BIO
MARKET DEEP DIVE · IRELAND / EXECUTION
Ireland — execution
A hybrid UK/Australian strategy: traditional marketing to grow pharmacy footprint, with GP and dentist detailing. No NHS plus a strong
herbal-medicine tradition make Ireland well suited.
PARTNERS & DISTRIBUTORS
Uniphar
Retail pharmacy
Pure and Natural
Health-store & practitioner channel
TDS
3PL hub — EU gateway, serves UK
COMPETITORS — WHAT WE DO BETTER
Alflorex
Them: Clinically-backed, strong pharmacy brand
Us: Broader range, owned IP, multi-indication
OptiBac
Them: Retail presence, promotional
Us: Never discounted; practitioner positioning
HOW WE SCALE
● Traditional marketing to grow pharmacy
footprint
● GP and dentist detailing programme
● Deepen the five secured banner groups
● Leverage TDS hub for EU expansion
16
BIOME AUSTRALIA · ASX: BIO
Bio-Kult
Them: Mass pharmacy presence
Us: Owned IP and recommendation-driven demand
MARKET DEEP DIVE · NEW ZEALAND / OPPORTUNITY
New Zealand
A foundation year. Practitioner base and ProPharma distribution in place; the Propharma wholesale pharmacy launch in Q4 FY26 is the
near-term catalyst.
LAUNCHING NATURAL HEALTH INDUSTRY
NZ$2.3bn
Natural Health Products NZ
PHARMACY UNIVERSE
~1,100
Community pharmacies
THE MOAT Practitioner-only • Clinically backed • Non discounted • Unlike any brand in any market
17
CHANNELS
Pharmacy Practitioner Health Food
BIOME AUSTRALIA · ASX: BIO
MARKET DEEP DIVE · NEW ZEALAND / EXECUTION
New Zealand — execution
Distribution established through ProPharma, corporate pharmacy launching through Green Cross in Q4 FY26.
PARTNERS & DISTRIBUTORS
ProPharma
Pharmacy Distribution
Pacific Health
Naturopaths and integrative clinics
NutriScript
Naturopaths and integrative clinics
COMPETITORS — WHAT WE DO BETTER
Clinicians
Them: Practitioner heritage, broad range
Us: Proprietary strains, clinical trials, AU manufacturing
GO Healthy
Them: Market-leading mass brand
Us: Practitioner-only; never discounted
Lifestream
Them: Natural-health positioning
Us: Owned IP and recommendation-driven model
HOW WE SCALE
● Launch Green Cross corporate roll-out
● Expand banner relationships
● Deepen practitioner channel
● Grow ProPharma distribution
18
BIOME AUSTRALIA · ASX: BIO
PRICING POWER
Pricing and margin architecture
One global pricing architecture. Biome Daily Probiotic anchors a premium, non-discounted position in every market, in local currency.
AUSTRALIA
A$34.95
Home market RRP
CANADA
C$46.99
Fullscript / retail, ex tax
UK
£29.95
Practitioner RRP
IRELAND
€36.95
Uniphar retail
NEW ZEALAND
NZ$39.95
ProPharma RRP
One architecture
Consistent premium tier across every market,
benchmarked to the AU home position.
No discounting
FY26 group growth was entirely volume-led, with
blended ASP held flat year-on-year. No
promotional erosion of brand equity.
Margin-accretive offshore
Practitioner mix lifts international gross margin
7pp above the domestic blend.
Biome Daily recommended retail price per market. Prices include local taxes except Canada (ex tax). Shown to illustrate global pricing architecture.
BIOME AUSTRALIA · ASX: BIO 19
INTERNATIONAL PREMIUM Every offshore market prices above the Australian home RRP in AUD-equivalent terms — corroborating the 68%
international gross margin.
SUPPLY CHAIN / EU GATEWAY
Northern Ireland hub: gateway to mainland Europe
The TDS 3PL hub sits in Northern Ireland, supplying mainland Europe directly and serving the UK alongside.
Northern Irish Advantage
Located within the UK single market — with
unique access to free trade within the EU.
Serves the UK too
Short-lead supply into UK and Irish customers
from the same hub.
Gateway to Europe
Platform to expand into continental EU markets
without setting up new infrastructure.
Continuity
In-region buffer stock reduces stock-out risk for
partner networks.
EU North
EU
Central
EU South
United Kingdom
TDS HUB · IRELAND
BIOME AUSTRALIA · ASX: BIO 20
MANUFACTURING / THE STEP CHANGE
Onshore manufacturing - Specialty Probiotics Australia (SPA)
Australian onshore manufacturing under the June 2026 SPA agreement commences September 2026 — the step change that lets the
international platform scale.
Small-batch agility
Local small-batch runs with
market-specific packaging —
produce what each market
needs, when it needs it.
Faster and more
efficient
Shorter production lead times
onshore, cutting the gap
between demand signal and
stock in market.
Premium finish
Higher-quality local finish,
consistent with the brand’s
premium, practitioner-only
positioning.
Lower COGS
Onshore economics reduce
landed cost per unit —
structurally supportive of gross
margin.
HOW IT COMES TOGETHER
SPA · Australia
Onshore manufacture
→ TDS · Ireland
EU gateway hub
→ Four markets + B2B2C
Practitioner-led demand
Commercial supply agreement executed June 2026; production from September 2026. Benefits stated are directional; no quantified guidance is given.
BIOME AUSTRALIA · ASX: BIO 21
NEW INITIATIVE / BIOME B2B2C & eSCRIPT PORTAL
Direct wholesale and e-scripts for practitioners
Launching H1 FY27: a direct wholesale model and e-script portal that lets practitioners prescribe Biome products directly. The UK is the
test market for a global roll-out.
01
Practitioner prescribes
HCP issues an e-script directly through
the Biome portal — no intermediary.
→
02
Biome fulfils direct
Direct wholesale model: order routed,
dispatched and supported by Biome.
→
03
Patient receives
Product delivered to the patient,
endorsed by their practitioner.
Relationship retained.
Practitioner control
Practitioners prescribe directly — deepening the
practitioner-only model, not diluting it.
UK as test market
Proven in the UK hub first, then rolled out globally
on the same platform.
Margin & data
Direct wholesale captures margin and first-party
demand data at source.
Planned launch H1 FY27. Rollout timing and functionality subject to development.
BIOME AUSTRALIA · ASX: BIO 22
GROSS MARGIN
International gross margin
Estimated international gross margin of ~68% in FY26, seven percentage points above the domestic blend.
Why the premium exists
The 7pp premium reflects channel mix, not pricing.
International revenue weights toward practitioner-led,
recommendation-driven sales where shelf, banner and
promotion overhead are absent.
Domestic and international split is estimated. Margin achieved in FY26; not a forward expectation.
BIOME AUSTRALIA · ASX: BIO 23
BLENDED GROSS MARGIN · FY26
61%
Domestic
~68%
International
CAPABILITY AND PEOPLE
International team
12 international FTE, each a localised connection point, supported by centralised regulatory, supply, science and finance from Australia.
CANADA
3
GM, Sales Manager, territory
and education resourcing.
UNITED KINGDOM
4
Channel, education, ops and
trade-event resourcing.
IRELAND
3
Local commercial team for
Uniphar and practitioner
growth.
NEW ZEALAND
2
Full-time Practitioner
Education consultants.
CENTRALISED FROM AUSTRALIA Regulatory · Quality · Supply chain · Science & research · Finance
BIOME AUSTRALIA · ASX: BIO 24
FY27 OUTLOOK
FY27 priorities
Four markets past proof point. The platform, people and channels are in place to scale.
FOUR PILLARS OF READINESS
Established markets
Four markets past proof point, contributing structurally
Brand trust earned
Practitioner and pharmacy channels validating the model
People in place
12 international FTE embedded and executing
Distribution set to scale
~2,000 distribution points, EU gateway live, B2B2C launching H1 FY27
FY27 OPERATIONAL PRIORITIES
● Quebec market unlock and continued Canadian account growth
● New Canadian pharmacy chains launching
● UK banner conversion
● B2B2C digital health platform launch (H1 FY27)
● Ireland pharmacy expansion via Uniphar and new pharmacy
banners launching
BIOME AUSTRALIA · ASX: BIO 25
BEYOND FY27
Reviewing strategic opportunities
A disciplined, evidence-led model proven across four jurisdictions. Any new market must clear the bar the first four did: practitioner-led
entry, clinical evidence, and disciplined economics.
MARKETS PAST PROOF POINT
4
INT'L GROSS MARGIN, FY26
~68%
INT'L DISTRIBUTION POINTS
~2,000
FURTHER MARKETS UNDER STRUCTURED REVIEW
A pipeline of additional markets is under active evaluation. Consistent with our approach to date, markets will be identified only
once regulatory pathways and commercial agreements are sufficiently advanced.
No commitment to entry has been made in respect of any market under review.
BIOME AUSTRALIA · ASX: BIO 26
FY26 INTERNATIONAL MARKETS
Four active markets, one operating
model
Practitioner-only · Clinically backed · Never discounted
Biome Australia Limited · ASX: BIO
Share your feedback
Discover